Zhongxin Finance, January 11 (Reporter Zhang Ni) Luo Yongqing, President of Tengsheng Biopharmaceutical Biotechnology Co., Ltd. and General Manager of Greater China, and CEO of Tengsheng Huachuang Medical Technology Co., Ltd., told the "China New Observation" column of Chinanews.com, In the past year, in the face of the continuous development of the global new crown epidemic and the continuous mutation of the virus, as an innovative force in the field of infectious diseases, Tengsheng Biopharma brought the first new crown neutralizing antibody treatment drug to China, which brought zero benefits to the prevention and control of the epidemic. breakthrough.
He said 2022 will remain a challenging year for the pharmaceutical industry.
It is hoped that more pharmaceutical companies and capital can actively participate in the research and development of drugs for public health diseases.
Tengsheng Biopharma will also continue to uphold its mission of addressing major public health challenges through breakthrough innovation and insight, with the courage to make breakthroughs and move forward.
(Finish)